JP2023512366A5 - - Google Patents

Info

Publication number
JP2023512366A5
JP2023512366A5 JP2021564953A JP2021564953A JP2023512366A5 JP 2023512366 A5 JP2023512366 A5 JP 2023512366A5 JP 2021564953 A JP2021564953 A JP 2021564953A JP 2021564953 A JP2021564953 A JP 2021564953A JP 2023512366 A5 JP2023512366 A5 JP 2023512366A5
Authority
JP
Japan
Prior art keywords
subject
pharmaceutical composition
brain
brain tissue
volume
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021564953A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512366A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/050879 external-priority patent/WO2021156769A1/en
Publication of JP2023512366A publication Critical patent/JP2023512366A/ja
Publication of JP2023512366A5 publication Critical patent/JP2023512366A5/ja
Priority to JP2025153760A priority Critical patent/JP2026001009A/ja
Pending legal-status Critical Current

Links

JP2021564953A 2020-02-03 2021-02-03 リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法 Pending JP2023512366A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025153760A JP2026001009A (ja) 2020-02-03 2025-09-17 リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062969568P 2020-02-03 2020-02-03
US62/969,568 2020-02-03
US202063029154P 2020-05-22 2020-05-22
US63/029,154 2020-05-22
US202063072714P 2020-08-31 2020-08-31
US63/072,714 2020-08-31
PCT/IB2021/050879 WO2021156769A1 (en) 2020-02-03 2021-02-03 Methods for treating neurological symptoms associated with lysosomal storage diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025153760A Division JP2026001009A (ja) 2020-02-03 2025-09-17 リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法

Publications (2)

Publication Number Publication Date
JP2023512366A JP2023512366A (ja) 2023-03-27
JP2023512366A5 true JP2023512366A5 (https=) 2024-02-13

Family

ID=74592326

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021564953A Pending JP2023512366A (ja) 2020-02-03 2021-02-03 リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法
JP2025153760A Pending JP2026001009A (ja) 2020-02-03 2025-09-17 リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025153760A Pending JP2026001009A (ja) 2020-02-03 2025-09-17 リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法

Country Status (12)

Country Link
US (1) US12083115B2 (https=)
EP (1) EP4100009A1 (https=)
JP (2) JP2023512366A (https=)
KR (1) KR20220136887A (https=)
CN (1) CN115427038A (https=)
AU (1) AU2021215396B2 (https=)
BR (1) BR112022014553A2 (https=)
CA (1) CA3166777A1 (https=)
IL (1) IL295255A (https=)
MX (1) MX2022009477A (https=)
TW (1) TW202142236A (https=)
WO (1) WO2021156769A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
CN114040762A (zh) 2019-02-04 2022-02-11 建新公司 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病
JP2023512366A (ja) 2020-02-03 2023-03-27 ジェンザイム・コーポレーション リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法
AU2021311131B2 (en) 2020-07-24 2026-02-19 Genzyme Corporation Pharmaceutical compositions comprising venglustat
WO2025219952A1 (en) * 2024-04-19 2025-10-23 Genzyme Corporation Venglustat for use in methods for reducing disease related biomarker levels in patients with ganglioside storage disorders
WO2025219951A1 (en) * 2024-04-19 2025-10-23 Genzyme Corporation Venglustat for use in methods for reducing disease related biomarker levels in patients with ganglioside storage disorders

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB725228A (en) 1952-06-19 1955-03-02 Roche Products Ltd Substituted carbamic acid esters and process for the manufacture thereof
BE640616A (https=) 1962-12-19
NL130759C (https=) 1965-10-07
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4593034A (en) 1984-04-06 1986-06-03 A. H. Robins Company, Inc. 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides
AU611976B2 (en) 1987-12-24 1991-06-27 John Wyeth & Brother Limited Aroyl urea and carbamic acid derivatives of azabicyclo compounds
DE3878235T2 (de) 1988-08-04 1993-06-03 Synthelabo Antischizophren-wirksame s-n-(1-azabicyclo (2.2.2.)oct-3-yl)benzamide und thiobenzamide.
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
IT1228293B (it) 1989-02-06 1991-06-07 Angeli Inst Spa Benzoderivati di composti eterociclici contenenti azoto.
DK443489D0 (da) 1989-09-08 1989-09-08 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
GB9106571D0 (en) 1991-03-27 1991-05-15 Erba Carlo Spa Derivatives of substituted imidazol-2-one and process for their preparation
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
AU685225B2 (en) 1994-02-10 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
JPH08198751A (ja) 1995-01-19 1996-08-06 Yamanouchi Pharmaceut Co Ltd カルバメート誘導体
KR19990067403A (ko) 1995-11-08 1999-08-16 이곤 이 버그 1-아자바이시클로헵탄 유도체 및 이의 약제학적용도
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
JP2000515881A (ja) 1996-07-29 2000-11-28 フアーマシア・アンド・アツプジヨン・アー・ベー アリールシクロアルカンカルボン酸エステル、その使用、薬剤組成物および調製
IL135578A0 (en) 1997-10-29 2001-05-20 Genzyme Corp Compositions and methods for treating lysosomal storage disease
US6468998B1 (en) 1998-11-02 2002-10-22 Mitsubishi Pharma Corporation Pyrrolidine compounds and medicinal utilization thereof
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
FR2791678B1 (fr) 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
KR20020084116A (ko) 2000-02-07 2002-11-04 애보트 게엠베하 운트 콤파니 카게 2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
KR100751981B1 (ko) 2000-06-27 2007-08-28 라보라토리오스 살바트, 에스.에이. 아릴알킬아민으로부터 유도된 카바메이트
AU2001284645A1 (en) 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
NZ526580A (en) 2000-12-22 2005-04-29 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as M3 antagonists
ATE348829T1 (de) 2001-02-06 2007-01-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen
JP2003267977A (ja) 2002-03-14 2003-09-25 Yamanouchi Pharmaceut Co Ltd キヌクリジン誘導体
DE10211415A1 (de) 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
AU2003246942B2 (en) 2002-07-17 2009-06-25 Idorsia Pharmaceuticals Ltd Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
JPWO2004011430A1 (ja) 2002-07-25 2005-11-24 アステラス製薬株式会社 ナトリウムチャネル阻害剤
SE0202430D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
JP4750421B2 (ja) 2002-12-06 2011-08-17 ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト α7受容体結合コリン作動性アゴニストを用いる炎症の阻害
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
TW200529860A (en) 2003-12-22 2005-09-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
JP2007186422A (ja) 2004-01-28 2007-07-26 Astellas Pharma Inc アリールスルフィド誘導体
JP2008504282A (ja) 2004-06-23 2008-02-14 ザ ファインスタイン インスティテュート フォー メディカル リサーチ コリンレセプターの薬理活性により腸閉塞を処置する方法
EP1811991B1 (en) 2004-11-10 2018-11-07 Genzyme Corporation Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis
JP2008545776A (ja) 2005-06-11 2008-12-18 ヴァーナリス アールアンドディー リミテッド 癌および自己免疫疾患の治療における使用のためのピラゾール−置換ベンズイミダゾール誘導体
CN101312968A (zh) 2005-09-23 2008-11-26 记忆药物公司 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑、吡唑并吡啶、异噻唑并吡啶及其制备和用途
SG131819A1 (en) 2005-11-07 2007-05-28 Chikka Pte Ltd Buddy-based cross-carrier messaging system
WO2007083978A1 (en) 2006-01-23 2007-07-26 Crystalgenomics, Inc. Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same
EP1976519A2 (en) 2006-01-27 2008-10-08 Yale University Cytisine and acetylcholine analogs and methods of treating mood disorders
EP2119716A4 (en) 2007-02-09 2011-06-01 Astellas Pharma Inc AZA BRIDGE CYCLE COMPOUND
MX2009010557A (es) 2007-03-30 2009-11-19 Amicus Therapeutics Inc Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
EP2170065A4 (en) 2007-06-20 2011-11-23 Merck Sharp & Dohme DIPHENYL SUBSTITUTED ALKANES
CA2706727A1 (en) 2007-11-29 2009-06-11 Michael S. Mcgrath Compositions and methods for treating lysosomal disorders
CA2731685A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
EP2154136A1 (en) 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof
WO2010091104A1 (en) 2009-02-06 2010-08-12 Exelixis, Inc. Glucosylceramide synthase inhibitors
WO2010091164A1 (en) 2009-02-06 2010-08-12 Exelixis, Inc. Inhibitors of glucosylceramide synthase
WO2010121963A1 (en) 2009-04-21 2010-10-28 Nerviano Medical Sciences S.R.L. Resorcinol derivatives as hsp90 inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP2959902A1 (en) 2009-07-23 2015-12-30 Novartis AG Use of azabicycloalkyl derivatives for the treatment or prevention of ataxia
SI3998078T1 (sl) 2009-08-28 2026-02-27 Genzyme Corporation Encimsko nadomestno zdravljenje z naraščajočim odmerkom za zdravljenje pomanjkanja kisle sfingomielinaze
US20110183938A1 (en) 2009-12-16 2011-07-28 Genentech, Inc. 1,7-diazacarbazoles and methods of use
KR101500915B1 (ko) 2010-11-12 2015-03-10 시오노기세야쿠 가부시키가이샤 6,7-불포화-7-카르바모일 모르피난 유도체의 결정 및 그의 제조 방법
KR101987736B1 (ko) * 2011-03-18 2019-06-11 젠자임 코포레이션 글루코실세라마이드 합성효소 억제제
US20140228575A1 (en) 2011-06-22 2014-08-14 Isochem Process for the Preparation of Solifenacin and Salts Thereof
CA2840224C (en) 2011-06-22 2019-08-13 The General Hospital Corporation Treatment of proteinopathies
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
US9655946B2 (en) 2012-09-11 2017-05-23 Hospira Australia Pty Ltd. Daptomycin formulations and uses thereof
JO3713B1 (ar) 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
MX365464B (es) 2013-03-15 2019-06-04 Genzyme Corp Prodecimiento para preparar inhibidores de la glucosilceramida sintasa.
EP3079695B1 (en) 2013-12-11 2021-03-17 Genzyme Corporation Glucosylceramide synthase inhibitors
TW201642855A (zh) * 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法
EP3412296B1 (en) * 2016-02-05 2025-11-12 Kyungpook National University Industry-Academic Cooperation Foundation Pharmaceutical composition containing stem cell in which vascular endothelial growth factor is overexpressed as effective ingredient for preventing or treating neurodegenerative disease
CN113645969A (zh) 2019-02-04 2021-11-12 建新公司 用于治疗与溶酶体贮积症相关的症状和病症的方法
CN114040762A (zh) 2019-02-04 2022-02-11 建新公司 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病
CN113395964A (zh) * 2019-02-04 2021-09-14 普瑞尼亚神经治疗有限公司 用于帕金森氏病和与帕金森症相关的其它疾病的低剂量普利多匹定
JP2023512366A (ja) 2020-02-03 2023-03-27 ジェンザイム・コーポレーション リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法

Similar Documents

Publication Publication Date Title
JP2023512366A5 (https=)
US10543179B2 (en) Dosage regimen of an S1P receptor modulator
JP2003510273A (ja) 神経障害性の疼痛の治療のためのレチガビンの使用
EP1948177B1 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
US10285981B2 (en) Compositions and methods for treating amyotrophic lateral sclerosis in responders
ES2813674T3 (es) Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
JP2012500800A (ja) 神経因性疼痛の治療法
US20250288544A1 (en) Probenecid for use in treating epileptic diseases, disorders or conditions
JP2021152060A (ja) アカンプロセートおよびd−サイクロセリンを使用する組み合わせ療法
US20060241133A1 (en) Electrically variable pneumatic structural element
TW202231661A (zh) 安全投予抗tau抗體之方法
EP3490546A1 (en) Methods of treating or preventing amyloid related imaging abnormalities associated with alzheimer's disease treatment
ES2316808T3 (es) Empleo de dihidroimidazolonas para el tratamiento de la epilepsia en perros.
JP7337081B2 (ja) レストレスレッグズ症候群を治療するための治療薬
TWI864376B (zh) 焦慮症處置用組成物及處置方法
CN113242735A (zh) 使用氨基甲酸酯化合物预防、缓解或治疗并发的癫痫发作
RU2785842C2 (ru) Применение пробенецида для лечения эпилептических заболеваний, нарушений и состояний
ES2199541T3 (es) Aplicacion del 2-amino-6-trifluorometoxi-benzotiazol para la prevencion o el tratamiento de disfunciones del cerebelo.
JP2007523827A (ja) 混合性白血病遺伝子の再構成を伴う急性リンパ芽球性白血病の処置方法
US20170112789A1 (en) Intravenous baclofen and methods of treatment
CA3070178C (en) Probenecid for use in treating epileptic diseases, disorders or conditions
TW202510848A (zh) 用於治療癌症之psma靶向放射性藥物
CN119384295A (zh) 以纹状体纹状小体的多巴胺d1信号为靶点的强迫性障碍的药物疗法
EA048938B1 (ru) Комбинация антагониста cxcr7 с модулятором рецептора s1p1
US20190038624A1 (en) Use of abelson tyrosine kinase inhibitor in treatment of multiple system atrophy